Dec 6 (Reuters) - Editas Medicine Inc:
* EDITAS MEDICINE ANNOUNCES POSITIVE SAFETY AND EFFICACY DATA FROM THE FIRST TWO PATIENTS TREATED IN THE RUBY TRIAL OF EDIT-301 FOR THE TREATMENT OF SEVERE SICKLE CELL DISEASE
* EDITAS MEDICINE INC - EDIT-301 WAS WELL-TOLERATED AND DEMONSTRATED A SAFETY PROFILE
* EDITAS MEDICINE INC - BOTH PATIENTS TREATED WITH EDIT-301 SUCCESSFULLY ENGRAFTED AND ARE FREE OF VASO-OCCLUSIVE EVENTS DURING FOLLOW-UP PERIOD
* EDITAS MEDICINE - FIRST PATIENT TREATED HAS A TOTAL HEMOGLOBIN LEVEL OF 16.4 G/DL AND 45.4% FETAL HEMOGLOBIN FIVE MONTHS AFTER TREATMENT WITH EDIT-301 Source text for Eikon: Further company coverage: